Immune therapy is 4th main cancer therapy. Dendritic cell (DC) and macrophage are the first lie of immune cells to be able to phagocyte cancer cells to present cancer antigen peptides to natural killer T (NKT) cells and cytotoxic T  (CTL) cells. For proper activation of an anti-tumor immune response, the antigen-presenting cells (APC), in particular DCs. The processes contain presentation of tumor antigens in complexes with MHC class I and II molecules on the surface of DCs to T-cell receptors (TCR). The signal is transmitted via interaction of co-stimulatory and adhesion molecules expressed on the surface of DCs to their receptors on T cells.  T-cell stimulatory cytokines by DCs (are professional antigen-presenting cells, the main function of which is to capture, process, and present antigen material to T lymphocytes in complex with MHC I and II molecules, activating an antigen-specific T-lymphocyte immune respons. It was understood how the antigen-specific T-cell immune response is triggered, and DCs were shown to play a principal role in this process.